Drugs / Gamma Delta Tocotrienols
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02634606 Comparator | Mar 2011 → Nov 2015 | hyperlipidemia | University of California, Los Angeles | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gamma Delta Tocotrienols | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02634606 ↗ |
| Action | Inhibit | “γ-tocotrienol appears to inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase” NCT02634606 ↗ |
| Modality | Small molecule | “Tocotrienols are naturally-occurring compounds in foods” NCT02634606 ↗ |
| Route | Oral | “Subjects will be asked to take 2 tablets per day” NCT02634606 ↗ |
| Target | HMGCR | “γ-tocotrienol appears to inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase” NCT02634606 ↗ |